Transgene SA
PAR:TNG

Watchlist Manager
Transgene SA Logo
Transgene SA
PAR:TNG
Watchlist
Price: 1.285 EUR 1.98%
Market Cap: 170.6m EUR

Profitability Summary

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Past Growth

Analyzing past growth in Revenue, Operating Income, and Net Income allows investors to assess the company's profitability and operational efficiency. Consistent improvement in these metrics typically signals long-term strength and stability.

Show More Less

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Show More Less

Earnings Waterfall
Transgene SA

Revenue
8.8m EUR
Operating Expenses
-43.4m EUR
Operating Income
-34.6m EUR
Other Expenses
-558k EUR
Net Income
-35.1m EUR

Margins Comparison
Transgene SA Competitors

Country Company Market Cap Operating
Margin
Net
Margin
FR
Transgene SA
PAR:TNG
170.6m EUR
-392%
-398%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
-21 040%
US
Abbvie Inc
NYSE:ABBV
417.6B USD
33%
4%
US
Amgen Inc
NASDAQ:AMGN
181.6B USD
34%
19%
US
Gilead Sciences Inc
NASDAQ:GILD
157.3B USD
39%
28%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
108.4B USD
39%
31%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
-392%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.6B USD
28%
32%
AU
CSL Ltd
ASX:CSL
88.6B AUD
26%
19%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
57.2B USD
-7%
-13%
NL
argenx SE
XBRU:ARGX
48.5B EUR
22%
43%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Show More Less

Return on Capital Comparison
Transgene SA Competitors

Country Company Market Cap ROE ROA ROCE ROIC
FR
Transgene SA
PAR:TNG
170.6m EUR
1 665%
-77%
-176%
-151%
FR
Pharnext SCA
OTC:PNEXF
6T USD
115%
-391%
275%
3 093%
US
Abbvie Inc
NYSE:ABBV
417.6B USD
139%
2%
20%
28%
US
Amgen Inc
NASDAQ:AMGN
181.6B USD
82%
8%
17%
15%
US
Gilead Sciences Inc
NASDAQ:GILD
157.3B USD
41%
14%
25%
19%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
108.4B USD
22%
16%
23%
25%
US
Epizyme Inc
F:EPE
94.1B EUR
-877%
-67%
-73%
-182%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.6B USD
15%
12%
11%
12%
AU
CSL Ltd
ASX:CSL
88.6B AUD
16%
8%
12%
10%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
57.2B USD
-258%
-7%
-6%
-10%
NL
argenx SE
XBRU:ARGX
48.5B EUR
30%
26%
15%
61%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

Show More Less